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A paper by Sinclair and colleagues1 in Blood challenges, on the basis of observations on cell 
lines, the concept that erythropoietin has activities unrelated to erythrodifferentiation. 
Sinclair and colleagues, based at Amgen, have published six papers since 2006 focused on 
whether the erythropoietin receptor (EPOR) is expressed by tumour cells—a fact that, if 
true, could have adverse effects for the use of erythropoietin in cancer. They conclude that 
EPOR is not expressed by many of the cells previously reported to express EPOR and 
exhibit cytoprotection by erythropoietin, and question the entire concept that erythropoietin 
is active on non-haemopoietic cells.
Although sometimes data from one laboratory are not replicated in another, many 
investigators have reported trophic or antiapoptotic effects of erythropoietin on many cells, 
including those that Sinclair and colleagues report in tabular form without presenting their 
original data. In fact, over the past 10 years, multiple investigators have shown that 
erythropoietin is tissue-protective, anti-inflammatory, and promotes neurogenesis and 
angiogenesis.
The observation that erythropoietin is neuroprotective in vivo2 ignited substantial interest in 
its roles and possible therapeutic use in various diseases. Searching for “erythropoietin AND 
protect*”, PubMed gives 863 hits of which we identified 346 research papers reporting a 
protective or reparative action, and only ten a lack of extra-haemopoietic effects.
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Having no data to compare with previous studies, it is difficult to understand whether 
“inconsistent, irreproducible and at best modest (10–20%) effects”1 refers to the 
inconsistency of the effect or to Sinclair and colleagues' experimental technique.
Sinclair and colleagues expand their conclusions further by stating that in vivo studies of 
erythropoietin in animal models of damage are faulty and that they “do not believe [that] 
clinical studies examining an alleged ‘direct’ effect of ESAs [erythropoiesis-stimulating 
agents] on heart or brain function or repair are well founded”.1 The term “alleged” is a 
hyperbole when referring to the tissue-protective actions of erythropoietin that, 
independently of the receptors implicated, are supported by hundreds of studies, two meta-
analyses,3,4 and some clinical trials, although we agree that caution should be used because 
of potential side-effects.5
Cratylus, discussing with Plato, stated that names express the essence of the thing. This is 
hardly the case for cytokines: look at tumour necrosis factor or inter leukin 1. Although, 
from a pharmaceutical perspective, it would be convenient if erythropoietin had no activities 
outside erythropoiesis, this is wishful thinking. The field would be better served by efforts to 
understand the full spectrum of erythropoietin's actions.
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